Harvard Apparatus Regenerative Technology

Harvard Apparatus Regenerative Technology (HRGN) is a clinical-stage biotechnology company with a mission to regenerate damaged organ tissue using a patient's own stem cells and a proprietary bioabsorbable scaffold. Its key achievement is the FDA approval of an IND and the initiation of a Phase 1 clinical trial for its Cellspan Esophageal Implant, following a landmark first-in-human case at the Mayo Clinic. The company's strategy focuses on addressing severe, unmet medical needs in hollow organ repair, starting with esophageal atresia and cancer, leveraging a platform technology with potential applications in tracheal and bronchial regeneration.

A proprietary bioengineering platform using a patient's own (autologous) stem cells seeded on a bioabsorbable, hollow tubular scaffold to guide the regeneration of functional tissue for damaged hollow organs, after which the scaffold is removed.

HRGN's primary competition is the entrenched standard of care (e.g., gastric pull-up, colonic interposition), which has significant drawbacks. Within regenerative medicine, it is one of few companies with an autologous, bioabsorbable scaffold approach in clinical trials for hollow organs, giving it a pioneering but high-risk position in a sparsely populated field.